)
4D Molecular Therapeutics (FDMT) investor relations material
4D Molecular Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.4D-150 profile and phase II evidence
4D-150 is designed as a continuous backbone therapy after one in-clinic intravitreal injection, potentially reducing treatment burden and helping preserve vision over time.
Its directed-evolution capsid enables low-dose intravitreal delivery; the payload combines aflibercept and VEGF-C RNAi to target four molecular pathways.
In recently diagnosed patients followed for two years, central subfield thickness was controlled and BCVA maintained; estimated treatment-burden reduction was ~90%, with roughly two-thirds needing no supplemental injections at two years.
At the phase III dose with topical steroid prophylaxis, mild inflammation occurred in a few patients during the first six months; all were inflammation-free from six months onward, with no significant serious or vision-threatening events described.
Phase III design and timing
4FRONT-1 and 4FRONT-2 are global trials with roughly 520–530 patients each; the primary endpoint is BCVA non-inferiority, with treatment-burden reduction also assessed.
Trials enroll front-line patients, exclude extreme CST, require an aflibercept response after loading, and use rescue criteria based on CST and vision to protect BCVA.
Readouts are expected in Q2 2027 for 4FRONT-1 and H2 2027 for 4FRONT-2; each study was expanded to roughly 525–530 patients.
Market and commercial opportunity
The global anti-VEGF market was described as ~$16B; newer bolus therapies have delivered about 20% incremental burden reduction, versus 80%–90% seen in the phase II program.
Intravitreal delivery is expected to fit existing U.S. ordering, inventory, and buy-and-bill reimbursement workflows; pricing remains under consideration, with a higher price point than a single anti-VEGF dose anticipated.
Management cited real-world discontinuation of bolus therapy by 60% of patients within five years and 40% within two years; reducing treatment burden could also ease clinic capacity constraints.
Physicians and patients were described as highly receptive to a continuous, potentially injection-free backbone therapy; management sees the next 12 months as informative for the field.
- 4D-150’s wet AMD readouts are due in 2027 as its DME Phase 3 advances.FDMT
Q3 2026 - Fully enrolled Phase III trials put 4D-150 on track for 2027 wet AMD readouts.FDMT
Stifel 2026 Healthcare Conference 2026 - 4D-150 targets continuous wet AMD control; phase III data are expected in 2027.FDMT
3rd Annual Guggenheim Healthcare Innovation Conference - 4D-150’s global Phase 3 trials test its potential as a wet AMD backbone therapy, with 2027 readouts projected.FDMT
Investor Day 2026 - 4D-150 advances toward Phase 3 readouts; 4D-710 shows durable CFTR expression.FDMT
Corporate presentation - 4D-150 targets a paradigm shift in wet AMD with major phase III data expected next year.FDMT
12th Annual Cantor Fitzgerald Global Healthcare Conference - 4D-150 gene therapy shows strong safety, efficacy, and commercial momentum in retinal diseases.FDMT
Morgan Stanley 24th Annual Global Healthcare Conference - 4D-150 and 4D-710 show strong clinical progress, reducing treatment burden and improving outcomes.FDMT
Corporate presentation - Q2 2026 revenue rose to $3.8M, but net loss widened to $72.9M as R&D spending increased.FDMT
Q2 2026
)
)
)
)
)
)
)
)